DYNDyne Therapeutics, Inc.

$3B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$506M-63.0% YoY

Gross Profit

-$2.4B-479.4% margin

Operating Income

-$412M-81.4% margin

Net Income

$76M15.0% margin

EPS (Diluted)

$0.47

Cash Flow

Operating Cash Flow

$585M

Free Cash Flow

$361M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$11.8B

Total Liabilities

$9.9B

Stockholders' Equity

$1.9B

Cash & Equivalents

$365M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$506M	$1.4B	-63.0%
Gross Profit	-$2.4B	-$915M	-165.1%
Operating Income	-$412M	-$640M	+35.6%
Net Income	$76M	-$1.2B	+106.1%

DYN FY 2017 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena